Clinical Trials Logo

Filter by:
NCT ID: NCT02455830 Active, not recruiting - Clinical trials for Neonatal Encephalopathy (Neonatal Hypoxic-ischemic Encephalopathy)

Cytokines Associated With Cord Blood Cell Therapy for Neonatal Encephalopathy

Start date: April 2015
Phase:
Study type: Observational

This is a observational study to assess the effects of and to explore the mechanisms of autologous umbilical cord blood cell therapy for neonatal encephalopathy by way of measuring serum cytokines.

NCT ID: NCT02455271 Completed - Insomnia Clinical Trials

Investigation of the Safety and Efficacy of Long Term Administration of Eszopiclone in Insomnia Patients

Start date: October 1, 2012
Phase:
Study type: Observational

To investigate the safety and efficacy of administration of eszopiclone for 6 months in insomnia participants.

NCT ID: NCT02454478 Completed - Clinical trials for Carcinoma, Renal Cell

Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)

Start date: July 1, 2015
Phase: Phase 1
Study type: Interventional

Phase 1 study to investigate the tolerability and safety of lenvatinib in combination with Everolimus in participants with unresectable advanced or metastatic RCC.

NCT ID: NCT02453555 Completed - Clinical trials for Diabetes Mellitus, Type 2

Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus

Start date: May 14, 2015
Phase: Phase 3
Study type: Interventional

This trial will compare the use of fixed dose combination of empagliflozin and linagliptin to linagliptin alone in patient with type 2 diabetes mellitus

NCT ID: NCT02453282 Active, not recruiting - Clinical trials for Non-Small-Cell Lung Carcinoma NSCLC

Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)

MYSTIC
Start date: July 21, 2015
Phase: Phase 3
Study type: Interventional

This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type locally advanced or metastatic NSCLC

NCT ID: NCT02453256 Completed - Systemic Sclerosis Clinical Trials

A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc)

focuSSced
Start date: November 20, 2015
Phase: Phase 3
Study type: Interventional

This study will assess the efficacy and safety of tocilizumab compared with placebo in participants with SSc across approximately 120 planned global study sites. The study will consist of a 48-week, double-blind, placebo-controlled period followed by a 48-week open-label treatment period. Participants will be assigned, in a 1:1 ratio, to double-blind treatment with active tocilizumab or matching placebo. In the open-label period, eligible participants from either arm may receive active tocilizumab.

NCT ID: NCT02452684 Completed - Insomnia Clinical Trials

Investigation of the Safety and Efficacy of Eszopiclone in Insomnia Patients

Start date: October 1, 2012
Phase:
Study type: Observational

To investigate the safety and efficacy of administration of eszopiclone for 4 weeks in insomnia patients.

NCT ID: NCT02452190 Completed - Asthma Clinical Trials

Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils

Start date: September 28, 2015
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to determine the effect of reslizumab (110 mg) administered subcutaneously every 4 weeks on clinical asthma exacerbations in adults and adolescents with asthma and elevated blood eosinophils who are inadequately controlled on standard-of-care asthma therapy.

NCT ID: NCT02451943 Active, not recruiting - Soft Tissue Sarcoma Clinical Trials

A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma

ANNOUNCE
Start date: September 14, 2015
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to evaluate the efficacy of the combination of doxorubicin plus the study drug known as olaratumab versus doxorubicin plus placebo in participants with advanced or metastatic soft tissue sarcoma.

NCT ID: NCT02451930 Completed - Clinical trials for Stage IV Non-Small Cell Lung Cancer

A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC

Start date: September 4, 2015
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to evaluate the safety and efficacy of the combination of necitumumab with pembrolizumab in participants with stage IV non-small cell lung cancer (NSCLC).